ストックスクリーナーアプリを入手
4.87
2.10%
0.10
アフターアワーズ：
4.87
Oric Pharmaceuticals Inc (ORIC) 最新ニュース
Alliancebernstein L.P. Trims Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
How the (ORIC) price action is used to our Advantage - news.stocktradersdaily.com
Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Vanguard Group Inc. - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Wellington Management Group LLP - Defense World
Corebridge Financial Inc. Has $247,000 Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by American Century Companies Inc. - Defense World
ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright - MSN
NEOS Investment Management LLC Buys New Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Strengthens Team with Strategic Equity Grants to Key New Hires - Stock Titan
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - The AM Reporter
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Consensus Target Price from Analysts - MarketBeat
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Oncology Pioneer ORIC Sets Stage for 2 Major Healthcare Conference Appearances - Stock Titan
Analysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.86 - Defense World
Swiss National Bank Has $504,000 Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Charles Schwab Investment Management Inc. Purchases 7,726 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC stock touches 52-week low at $6.31 amid market challenges By Investing.com - Investing.com South Africa
ORIC stock touches 52-week low at $6.31 amid market challenges - Investing.com Australia
PNC Financial Services Group Inc. Buys 2,520 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical - GlobeNewswire
Breakthrough: Novel Prostate Cancer Drug Demonstrates Powerful Two-Pronged Attack Strategy - Stock Titan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9%Time to Sell? - MarketBeat
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Wedbush Reiterates "Outperform" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% – Here’s What Happened - Defense World
(ORIC) Investment Report - news.stocktradersdaily.com
Wedbush Reaffirms Outperform Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc. - Defense World
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth - TipRanks
(ORIC) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
ORIC's Latest Employee Stock Grants: Key Details on Compensation Package - StockTitan
Rhumbline Advisers Purchases 4,072 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Projected to Post Earnings on Monday - MarketBeat
ORIC Pharmaceuticals Reports Progress in Cancer Trials - TipRanks
Wedbush Expects Increased Earnings for ORIC Pharmaceuticals - MarketBeat
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):